Psoriasis is increasingly being recognized as a serious systemic disease with associated quality-of-life impairment and disability, rather than a cutaneous disease, which denotes a merely cosmetic affliction. As perceptions of the disease continue to change, healthcare professionals will increasingly consider treatment non-optional and the use of expensive systemic drugs will increase, accelerating market growth.

Shreya Brahmbhat, Analyst at GBI Research, comments:
"In recent years, with the increased understanding of psoriasis pathogenesis, the development of several highly effective biologic drugs took place, which has revolutionized the treatment of moderate-to-severe plaque psoriasis. The emergence of IL-17 and IL-23 inhibitors has set a new benchmark for efficacy in moderate-to-severe psoriasis treatment and, owing to their precise targeting, could improve safety."--

The Asia-Pacific (APAC) psoriasis market is forecast to grow from $933.1m in 2017 to $1,997.3m in 2024, at a compound annual growth rate (CAGR) of 11.5%. Over the forecast period the prevalence of psoriasis is expected to increase significantly across the APAC markets, mainly due to alterations in environmental and lifestyle risk factors.